The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. - Wikidata - wikimedia - TriplyDB

The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.

The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.

http://www.wikidata.org/entity/Q45821336

about

From BILAG to BILAG-based combined lupus assessment-30 years on Systemic lupus erythematosus: review of synthetic drugs.The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis.Contemporary treatment of systemic lupus erythematosus: an update for clinicians.Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review.Treatment of lupus: impact on quality of life.Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.Damage assessment in ANCA-associated vasculitis.Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review.Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus.Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.It hasn't gone away: the problem of glucocorticoid use in lupus remains.Azathioprine Intolerance in Japanese Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis.[Established medications : new areas of application].Effect of immune tolerance induced by immature dendritic cells and CTLA4-Ig on systemic lupus erythematosus: An in vivo study.Efficacy of Cyclosporine in the Induction and Maintenance of Remission in a Systemic Lupus Erythematosus Patient Presenting with Macrophage-Activating Syndrome.Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis.Trial of SLE therapies in real-world settings Patient-reported outcome measures for use in clinical trials of SLE: a review

P2860

Q28081809-31001811-0D5F-42A1-9DAB-805CD62E1035 Q34498515-237D7FAF-9346-4EFD-A722-FEE63BA75929 Q35897121-AC830A77-8C7F-437D-9064-237566BFADA4 Q36443689-5FAC6250-FE83-4246-99AA-C5803A89E27F Q36802101-DC8095F5-AC17-406D-9AAC-2B980506AE56 Q37883966-98819853-21AB-467C-A72B-16F68A24E4D2 Q37954539-6A81BEE5-9E7B-4EF2-B1AC-6378004B7593 Q38043946-DD842567-6367-4FCF-926D-FBE8C0FC3A3B Q38101015-F3029E56-3981-4751-A37F-F3D5D2AA7705 Q38157723-E316BE9F-5CE4-4A57-A119-E5A04FD1C3E0 Q38205079-544D1845-18A3-4C39-BD60-9008CCCE6E91 Q39053147-7E4948F3-5E25-4AAF-9B85-7CFA96DA0B2D Q41073947-9C33040C-84EF-46E6-B9C7-709AC9C9D70E Q44480906-ACEC9CFA-DCED-48DE-9227-BDEA712C27E3 Q49875978-463B354A-2316-4A08-BC4B-F31DB5803542 Q54253814-BADD8E7B-5F24-44AF-8065-AA336EEAC336 Q55215256-C9ADA6BA-7BE2-498B-9155-7A42467DB3A7 Q56907356-65C5106F-1BC4-4279-852D-6A0E6F412083 Q58729793-5E18588C-D6AA-41A3-AB55-8EB6424B9D01

P2860

The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.

http://www.wikidata.org/entity/Q45821336

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

The BILAG multi-centre open ra ...... e in patients with severe SLE.

@en

The BILAG multi-centre open ra ...... e in patients with severe SLE.

@en-gb

The BILAG multi-centre open ra ...... e in patients with severe SLE.

@nl

type

label

The BILAG multi-centre open ra ...... e in patients with severe SLE.

@en

The BILAG multi-centre open ra ...... e in patients with severe SLE.

@en-gb

The BILAG multi-centre open ra ...... e in patients with severe SLE.

@nl

prefLabel

The BILAG multi-centre open ra ...... e in patients with severe SLE.

@en

The BILAG multi-centre open ra ...... e in patients with severe SLE.

@en-gb

The BILAG multi-centre open ra ...... e in patients with severe SLE.

@nl

P1433

Q45821336-3F338134-B7E6-475D-931C-43FF1F6054A2

P1476

Q45821336-6153224A-0571-4FB9-AA92-21A9352A5C75

P2093

Q45821336-01E26431-33DD-4486-9963-805B76EA0896

Q45821336-077FCBC9-6512-42F4-84C8-F5BBB823E738

Q45821336-245719D5-9032-4CE7-94AE-163288DA97EE

Q45821336-2F7832F8-7E54-4C4B-B568-20799600D71A

Q45821336-3201BD4D-3B3F-486D-841A-1C5FB8ACA2C1

Q45821336-41A2730C-466D-4915-AFDB-EBC0D328054F

Q45821336-50CCCE79-0F31-4C85-B726-354900D65440

Q45821336-555DDA58-45AF-435A-B41A-054DD21561CB

Q45821336-75AAFB85-C86B-46E2-914A-84F732F5D203

Q45821336-7616C45B-8663-49A1-A8E2-9D57C0A95D9A

P2860

Q45821336-0CFECDD8-69C6-49DE-894A-49FE048AF62F

Q45821336-2B8458F7-0B06-49E3-8114-891BC5D072F8

Q45821336-2C2BC082-0B27-44E5-8222-DD0D56C7C637

Q45821336-4CC5CADC-730C-4781-9E25-D05FE5776B5D

Q45821336-5F37BFC5-4221-4ED2-8292-862FD893878F

Q45821336-90B25BC7-01DE-44F4-B06E-98C6E9F80558

Q45821336-A4EDB804-CD5B-409A-B2DA-0997B0785CB5

Q45821336-C490C6E1-C6B9-43DF-BF61-E57BC1B14105

Q45821336-CF7AA73D-4C49-4D87-BAE4-8E689609B91C

Q45821336-DEF3382B-1F41-4473-86CE-F279B8AD08CC

P304

Q45821336-17C5E013-79D8-4B69-8184-C478CFCCE25D

P31

Q45821336-0A7704F4-50E7-4E0D-84A6-AC0EF4182C41

P356

Q45821336-CEFBD8B7-4303-4729-BE9E-9BCA63BE7E45

P433

Q45821336-EF5B900D-7815-48A2-9C15-9E0CD60EEDB7

P478

Q45821336-B79D0AC5-84A6-44C4-BAEE-30E7E899A737

P50

Q45821336-0139A87F-E6CF-4E60-BDCE-719BF74EEBE5

Q45821336-20C8155D-168B-4E4C-820F-C2D730E9C6A3

Q45821336-4F4F7C7D-39A1-4F04-A94A-A96F059E9DB1

P577

Q45821336-847B5B93-A72F-4795-9F32-EAE80FE1D64B

P698

Q45821336-3511A126-6590-4B8C-978C-0A4DF60DFB88

P921

Q45821336-9A7B11F1-5EA5-490A-A739-D9AA0CCCD54D

P356

P1433

P1476

The BILAG multi-centre open ra ...... e in patients with severe SLE.

@en

P2093

Alice Lorenzi

http://www.w3.org/2001/XMLSchema#string

Bridget Griffiths

http://www.w3.org/2001/XMLSchema#string

Christina Hallengren

http://www.w3.org/2001/XMLSchema#string

Deva Situnayake

http://www.w3.org/2001/XMLSchema#string

Gunnar Sturfelt

http://www.w3.org/2001/XMLSchema#string

Ian D Griffiths

http://www.w3.org/2001/XMLSchema#string

Kuntal Chakravarty

http://www.w3.org/2001/XMLSchema#string

Lee Suan Teh

http://www.w3.org/2001/XMLSchema#string

Mike Plant

http://www.w3.org/2001/XMLSchema#string

Mohammed Akil

http://www.w3.org/2001/XMLSchema#string

P2860

The treatment of lupus with cyclosporin A.

Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study.

Reporting attrition in randomised controlled trials.

The role of somatic mutation in the pathogenic anti-DNA response.

Cyclosporine: from renal transplantation to autoimmune diseases.

From BILAG to BLIPS--disease activity assessment in lupus past, present and future.

Trials to assess equivalence: the importance of rigorous methods.

Measuring patients' views: the optimum outcome measure.

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years

P304

723-732

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEP396

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

David A. Isenberg

Caroline Gordon

P577

2010-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20081225

http://www.w3.org/2001/XMLSchema#string

P921